Page contents Key factsDecisionRelated medicine informationKey facts Invented name LucentisLucentis Active Substance ranibizumab Therapeutic area Ophthalmology Decision number P/291/2010 PIP number EMEA-000527-PIP02-10 Pharmaceutical form(s) Solution for injection – single-use vialSolution for injection – single-use pre-filled syringe Condition(s) / indication(s) Treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia Route(s) of administration Intravitreal use Contact for public enquiries Novartis Europharm Limited paediatric.enquiries@novartis.comPhone: +41 61 324 1111Fax: +41 61 324 8001 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 22/12/2010DecisionP/291/2010: EMA decision of 22 December 2010 on the granting of a product specific waiver for ranibizumab (Lucentis), (EMEA-000527-PIP02-10)AdoptedReference Number: EMA/773522/2010 English (EN) (81.7 KB - PDF)First published: 24/01/2011Last updated: 24/01/2011ViewRelated medicine informationLucentisShare this page